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ABSTRACT
Objectives: Physical exercise has beneﬁcial effects on
cardiovascular risk factors. Knowledge about the effect
of exercise intensity, speciﬁcally walking speed, on
cardiovascular risk factors is limited. We report the
relationship between walking speed and changes in
cardiovascular risk factors in participants of a 12-day
walking tour to Santiago de Compostela.
Design: Prospective cohort study.
Setting: Single-centre study with healthy middle-aged
volunteers.
Participants: Healthy middle-aged men (n¼15) and
women (n¼14). Subjects using lipid-lowering
medication were excluded.
Intervention: Participants walked 281610 km of the
classical route to Santiago de Compostela in 12 days in
2009.
Primary and secondary outcome
measures: Walking speed was recorded and blood
pressure, weight, waist circumference, lipids and
glucose were measured every other day. Changes in
risk factors were compared between gender-pooled
groups with faster and slower walking speed. Second,
the relationship between walking speed and changes in
risk factors was quantiﬁed using a linear mixed effects
model.
Results: In the faster walking speed (4.660.2 km/h)
group, high-density lipoprotein cholesterol (HDL-c)
increased more than in the slower walking speed
(4.160.2 km/h) group (difference in change between
groups:0.20;95%CI 0.02to0.42 mmol/l),whilelow-
density lipoprotein cholesterol (LDL-c) and total
cholesteroldecreasedmoreintheslowerwalkingspeed
group (differences in changes between groups: LDL-c:
 0.50; 95% CI  0.88 to  0.12 mmol/l and total
cholesterol:  0.75; 95% CI  1.19 to  0.31 mmol/l). A
1 km/h higher walking speed was related to an increase
in HDL-c (0.24; 95% CI 0.12 to 0.30 mmol/l), LDL-c
(0.18; 95% CI  0.16 to 0.42 mmol/l) and total
cholesterol (0.36; 95% CI 0.12 to 0.60 mmol/l),
adjusted for age, gender, smoking, body mass index
and heart rate, during the whole walking tour.
Conclusions: Walking the same distance faster
improves HDL-c more, while LDL-c and total
cholesterol decrease more with lower walking speed
independent of changes in body weight in healthy
middle-aged subjects.
INTRODUCTION
Exercise has an inverse doseeresponse rela-
tionship with all-cause mortality and is
related to a lower risk of cardiovascular
disease and type 2 diabetes.
1 2 An important
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- Physical exercise has beneﬁcial effects on
cardiovascular risk factors; however, the know-
ledge about the effect of exercise intensity,
speciﬁcally walking speed, on cardiovascular
risk factors is limited.
- We report the relationship between walking
speed and changes in cardiovascular risk
factors in participants of a 12-day walking tour
to Santiago de Compostela.
Key messages
- In subjects walking a 12-day walking tour to
Santiago de Compostela, with long daily stages:
– walking the same distance with higher walking
speed was related to a higher increase in HDL-
c, while walking with lower walking speed was
related to larger decreases in LDL-c and total
cholesterol, adjusted for age, gender, smoking,
body mass index and heart rate.
– there was no relationship between walking
speed and changes in weight, waist circumfer-
ence, blood pressure, triglycerides or glucose.
Strengths and limitations of this study
- All subjects walked the same overall distance,
walking speed was measured and measurements
of cardiovascular risk factors were conducted
every other day.
- This is a small study with 29 participants walking
281 km in 12 days. Whether the results of this
study can be extrapolated to less exercise, and
other types of exercise is not known.
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Open Access Researchpart of these long-term beneﬁcial effects of exercise is
caused by improvement of classical cardiovascular risk
factors as physical activity lowers body weight, lowers
blood pressure, decreases insulin resistance and glucose
intolerance, lowers plasma triglycerides and increases
high-density lipoprotein cholesterol (HDL-c).
3 For these
reasons, physical exercise is widely recommended in
guidelines for treatment and prevention of cardiovas-
cular diseases.
4e6 Guidelines recommend a minimum
weekly physical activity equal to 150 min of brisk walking;
however, it is not speciﬁed at what intensity this exercise
should be preferably conducted.
4e6 Brisk walking or
shorter periods of exercise at a higher intensity (eg,
running) are considered equally effective.
4e6 However,
the results from studies evaluating the effects of exercise
intensity on cardiovascular risk factors are conﬂicting.
Several randomised clinical trials report no differences
between various intensities of exercise and conclude that
the total amount of exercise is more important than
exercise intensity.
7e10 Other studies conclude that exer-
cise at a higher intensity results in more beneﬁcial
changes in cardiovascular risk factors compared with
exercise at a lower intensity,
11e15 although not all studies
adequately control for differences in the total amount of
exercise.
12 13
Walking is one of the most accessible forms of physical
exercise and is, together with gardening, the major
component of leisure time physical activity.
16 Walking
speed is an easy parameter to express exercise intensity
and can be measured outside a laboratory with limited
resources. Results from large epidemiologic studies show
a relationship between increased walking speed and
a decreased risk for cardiovascular disease and
diabetes.
17e20 However, in these studies, the walking
speed was not measured but assessed using question-
naires where study participants estimated their usual
walking speed in broad categories such as ‘easy’,
‘average’ or ‘brisk’. Furthermore, these studies did not
evaluate the effects of walking speed on cardiovascular
risk factors.
In the Santiago study, 29 healthy middle-aged men and
women walked an equal distance consisting of 281 km at
their own individual preferred speed during 12 days in
Spain.
21 Marked inter-individual differences in changes
in cardiovascular risk factors were observed, predomi-
nantly in plasma lipids.
21 In the present study, we eval-
uated the inﬂuence of the measured walking speed on




Healthy male and female participants between 40 and
70 years of age were recruited by an announcement in
the magazine of the Dutch Saint James Fellowship. The
cohort size of 30 participants was based on a sample size
calculation to detect a difference in endothelial function
in the original Santiago study.
21 Subjects diagnosed as
having diabetes mellitus, uncontrolled hypertension or
a history of cardiovascular disease were excluded, as well
as subjects using lipid-lowering medication. There were
49 subjects responding to the advertisement and applied
for participation in the intervention group of the
Santiago study. One subject was not eligible because of
a history of diabetes mellitus, and one subject was not
eligible because of uncontrolled hypertension (systolic
blood pressure >170 mm Hg). From the remaining 47
eligible subjects, the ﬁrst 15 men and 15 women were
recruited for participation. After signing informed
consent form, but before start of the intervention
period, one female subject ended participation for
personal reasons. The design of the SANTIAGO study is
described in more detail elsewhere.
21 Brieﬂy, the
SANTIAGO study is a non-randomised intervention
study on the immediate and longer term effects of long
daily periods of walking on vascular function and
cardiovascular risk factors. Participants already intended
to walk part of the Santiago de Compostela pilgrimage.
The intervention consisted of walking part of the
Camino France ´s, the classical pilgrimage route to
Santiago de Compostela,
22 from 28th June to 10th July
2009, and covering 281 km between Hospital de O ´ rbigo
and Santiago de Compostela in Spain. Mean daily walked
distance was 2361 km, mean daily walked time
5.3960.36 h and mean steps per day 3105862154. All
participants completed the 12-day walking tour. For the
present study, the data of the 29 persons (15 men, 14
women) in the intervention group were used. The
SANTIAGO study was approved by the Medical Ethics
Committee of the UMC Utrecht. All participants gave
written informed consent before inclusion.
Measurement of walking speed
All participants used a diary to record their exact time of
departure, time of arrival and resting time, and the daily
walking time was calculated. Participants walked at their
individually preferred speed and were unaware that the
effects of their walking speed would become subject of
evaluation. All participants carried a pedometer (Digi-
walker SW-200; Yamax USA Inc., San Antonio, TX, USA),
measuring the number of steps daily. The participants
were instructed to wear the pedometer at their belt or
waistband at the left or right side of the body. From these
data, the walking speed was calculated in kilometres per
hour by dividing the total distance covered during the
study by the total walking time without including the
resting time. Walking speed was also expressed in steps
per hour by dividing the total number of steps by the
total walking time.
Measurement of cardiovascular risk factors
Measurements were conducted in Spain, at the start,
after arrival and at every other day in between during the
walking tour. All measurements were conducted in the
fasted state, before the start of the walking distance that
day. Measurements included weight, waist circumference
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The relation between walking speed and changes in cardiovascular risk factorsand blood pressure. Weight was measured without shoes
on the same balance during the whole study. Waist
circumference was measured in standing position with
a tape measure just above the iliac spine. Blood pressure
was calculated as the mean of three recordings in seated
position at the arm with the highest value at the baseline
visit, using an automated blood pressure device (Omron
705 IT; Hoofddorp, The Netherlands). Furthermore,
blood was obtained with a ﬁnger prick, for immediate
analysis of total cholesterol, HDL-c, triglycerides and
glucose with a portable LDX analyser (Cholestech
Corporation, Hayward, CA, USA). Low-density lipopro-
tein cholesterol (LDL-c) was calculated. No information
about dietary intake at baseline or during the study was
obtained. Participants were not instructed on their diet.
Data analyses
Continuous variables are expressed as mean6SD when
normal distributed and as median (IQR) in case of
skewed distribution. Categorical variables are expressed
as percentage (%). To analyse the role of walking speed
on the change in cardiovascular risk factors, we ﬁrst
compared the changes in cardiovascular risk factors
between participants walking with faster speed and
participants walking with slower speed. As there is no
generally accepted cut-off point for faster or slower
walking speed, the study population was divided based
on median walking speed, which also has the advantage
of creating groups of equal size. To prevent over-repre-
sentation of male participants in the high-speed group,
initially men and women were classiﬁed separately as
walking with faster or slower speed according to the
median speed of their sex. Thereafter, men and women
classiﬁed as faster walking speed were pooled in the
faster walking speed group, and men and women clas-
siﬁed as slower walking speed were pooled in the slower
walking speed group.
Second, a linear mixed effects model was used. In this
model, the relationship between walking speed and
changes in cardiovascular risk factors was adjusted for
differences in baseline values of cardiovascular risk
factors (using a random intercept) and for changes in
cardiovascular risk factors due to the progression of the
walking tour (using a ﬁxed time-dependent variable). To
investigate the effect of walking speed, an interaction
variable of walking speed and progression of the walking
tour (represented by the ﬁxed time-dependent variable)
was added to the model. The b coefﬁcients with 95% CIs
of these interaction terms are reported, denoting the
change in the speciﬁc risk factor per 2 days which is
related to an increase in walking speed of 1 km/h or
1000 steps/h. In model I, the unadjusted relationship
between walking speed and changes in cardiovascular
risk factors during the walking tour is presented. In
model II, adjustments were made for the potential
confounding variables age and gender. In model III,
additional adjustments were made for current smoking,
heart rate at baseline as the best available measure for
physical ﬁtness and baseline body mass index (BMI).
The main results are based upon this model. We
conducted an exploratory analysis with additional
adjustment for changes in body weight, to see if changes
in body weight during the walking tour were in the
causal pathway of the relationship between walking
speed and changes in blood lipids. In a sensitivity anal-
ysis, we additionally adjusted model III for baseline
characteristics with large differences between the low-
speed group and the high-speed group: systolic and
diastolic blood pressure, HDL-c, LDL-c and triglycerides.
For all analyses, SPSS V.15.0.1 was used.
RESULTS
Baseline characteristics
The faster walking speed group consisted of eight
men and seven women, 60.963.5 years old, who walked
with an average speed of 4.660.2 km/h, while the
slower walking speed group comprised seven men and
seven women, 58.166.6 years old (p value for age
between groups ¼0.17), with a mean walking speed of
4.160.2 km/h (p value for walking speed between
groups <0.01) (table 1). The median speed of the men
(n¼8) in the faster walking speed group was 4.62 (IQR
4.57e4.92), of the women in the faster walking speed
group (n¼7) 4.52 (IQR 4.24e4.62), of the men in the
slower walking speed group (n¼7) 4.23 (IQR 4.01e4.33)
and of the women in the slower walking speed group
(n¼7) 4.08 (IQR 3.94e4.10) km/h. Walking speed
varied during the 12-day pilgrimage from 4.37 (IQR
4.21e4.80) to 5.01 (IQR 4.78e5.16) in the faster walking
speed group and from 3.77 (IQR 3.50e4.07) to 4.30
(IQR 4.29e4.51) in the slower walking speed group.
Both groups walked a similar overall distance (28467
and 278611 km, respectively, p¼0.13). At baseline, the
systolic and diastolic blood pressure (148618/87610 vs
13868/8169 mm Hg, p values, respectively, 0.16 and
0.11) and heart rate (69610 vs 63610 beats/min,
p¼0.14) were higher in the faster walking speed group
compared with the slower walking speed group, and BMI
was lower (24.262.2 vs 27.062.7 kg/m
2,p <0.01). The
baseline lipid proﬁle was more favourable in the faster
walking speed group than in the slower walking speed
group (HDL-c 1.4560.39 vs 1.2460.36 mmol/l, p¼0.14;
LDL-c 3.460.5 vs 3.760.8 mmol/l, p¼0.22 and triglyc-
erides 1.160.5 vs 1.560.9 mmol/l, p¼0.12, respectively).
Changes in cardiovascular risk factors according to high or
low walking speed
The whole study population together showed decreases
in weight ( 1.461.8 kg), waist circumference
( 1.862.9 cm), LDL-c ( 0.6060.60 mmol/l), total
cholesterol ( 0.6060.70 mmol/l), triglycerides
( 0.3960.58 mmol/l) and systolic ( 969 mm Hg) and
diastolic ( 564 mm Hg) blood pressure during
the walking tour, while HDL-c increased (0.206
0.30 mmol/l).
21 Most of these changes were short lived;
after 2 months, there was only a signiﬁcant difference in
change of weight ( 2.0 kg; 95% CI  3.2 to  0.8) in the
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The relation between walking speed and changes in cardiovascular risk factorsparticipants walking the pilgrimage compared with
controls who did not walk the pilgrimage, while there
were no differences in changes in the other cardiovas-
cular risk factors between the groups.
21 In ﬁgure 1AeI,
the changes in cardiovascular risk factors for the faster
and slower walking speed groups during the walking
period are shown. The HDL-c in the faster walking speed
group increased more than in the slower walking speed
group (difference in change between the groups 0.20;
95% CI  0.02 to 0.42 mmol/l) (ﬁgure 1A). In the slower
walking speed group, the decreases in LDL-c and total
cholesterol were larger than in the faster walking speed
group (differences in changes in LDL-c between the
groups  0.50, 95% CI  0.88 to  0.12 and for total
cholesterol  0.75, 95% CI  1.19 to  0.31) (ﬁgure 1B,
C). Furthermore, weight decreased more in the slower
walking speed group (difference in change between the
groups  1.6, 95% CI  2.9 to  0.3 kg) (ﬁgure 1G). The
decreases in blood pressure were larger in the faster
walking speed group compared with the slower walking
speed group, although this difference was not statistically
signiﬁcant (difference in change between the groups
 4, 95% CI  11 to 3 mm Hg for systolic and  2, 95% CI
 5 to 1 mm Hg for diastolic blood pressure).
The quantitative inﬂuence of walking speed on the change in
cardiovascular risk factors
A 1 km/h higher walking speed is related to an increase
in HDL-c of 0.04 mmol/l (95% CI 0.02 to 0.05) per
2 days walking (table 2). For the whole 12-day walking
tour, the increase in HDL-c related to a 1 km/h higher
walking speed is then six times 0.04 mmol/l
(0.24 mmol/l, 95% CI 0.12 to 0.30). Furthermore,
a 1 km/h higher walking speed is related to an increase
in LDL-c of 0.03 (95% CI  0.01 to 0.07) mmol/l per
2 days walking and for total cholesterol, this is 0.06 (95%
CI 0.02 to 0.10) mmol/l per 2 days walking. For the
whole walking tour, a 1 km/h higher walking speed is
related to a LDL-c increase of 0.18 mmol/l (95% CI
 0.16 to 0.42) and an increase in total cholesterol of
0.36 mmol/l (95% CI 0.12 to 0.60) mmol/l. Lower or
higher walking speed was not related to differences in
blood pressure, weight, waist circumference, triglycer-
ides or glucose (table 2).
Similar analyses were performed with walking speed
expressed in steps per hour instead of kilometres per
hour, with similar results. A 1000 steps/h faster walking
speed was associated with increases in HDL-c of
0.01 mmol/l (95% CI 0.00 to 0.02), LDL-c of
0.02 mmol/l (95% CI 0.00 to 0.04) and total cholesterol
of 0.03 mmol/l (95% CI 0.00 to 0.05) per 2 days of
walking (table 3). Exploratory adjustment of the rela-
tionship between walking speed and changes in total
cholesterol, LDL-c, HDL-c and triglycerides for changes
in body weight did not change the results. Adjusting
all analyses for the total walked distance did not change
the results, as expected, as differences in total
walking distance between subjects were very small. In
a sensitivity analysis, we additionally adjusted for base-
line values of LDL-c, HDL-c, triglycerides and systolic
and diastolic blood pressure, which did not change the
results markedly.







Mean walking speed (km/h) 4.660.2 4.160.2 4.460.3
Walking speed range (km/h) 4.2e5.0 3.8e4.5 3.8e5.0
Number of steps/h 63096582 55476437 59416639
Total walking time (hours) 62636 8 636 5 64
Total walking distance (km) 28467 278611 281610
Male subjects 8 (53%) 7 (50%) 15 (52%)
Age (years) 60.963.5 58.166.6 59.565.3
Current smoking 3 (20%) 2 (14%) 5 (17%)
Systolic blood pressure (mm Hg) 148618 138618 143619
Diastolic blood pressure (mm Hg) 87610 81698 4 610
Heart rate (beats/minute) 69610 63610 66611
BMI (kg/m
2) 24.262.2 27.062.7 25.562.8
Waist circumference (cm) 88610 92611 90610
Glucose (mmol/l) 5.260.6 5.260.4 5.260.5
Total cholesterol (mmol/l) 5.360.7 5.660.8 5.560.8
LDL cholesterol (mmol/l) 3.460.5 3.760.8 3.560.7
HDL cholesterol (mmol/l) 1.4560.39 1.2460.36 1.3560.38
Triglycerides (mmol/l) 1.160.5 1.560.9 1.360.8
Total cholesterol:HDL-c ratio 3.861.0 5.062.1 4.461.7
LDL-c:HDL-c ratio 2.560.7 3.361.5 2.961.2
Baseline characteristics are shown according to walking speed and for all participants together. In order to avoid predominantly male subjects in
the faster walking speed group, the faster walking speed group is gender pooled and consists of the eight men and seven women with a walking
speed higher than the median speed for their gender.
BMI, body mass index; LDL, low-density lipoprotein; LDL-c, low-density lipoprotein cholesterol; HDL, high-density lipoprotein.
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The relation between walking speed and changes in cardiovascular risk factorsDISCUSSION
In the present study, it is shown that walking speed
signiﬁcantly relates to changes in the lipid proﬁle in
healthy middle-aged men and women walking 12 days to
Santiago de Compostela. A higher walking speed was
related to a higher increase in HDL-c and attenuated
decrease in LDL-c and total cholesterol, a relationship
that was not explained by changes in body weight.
Figure 1 (AeI) Changes in cardiovascular risk factors during the walking tour according to walking speed. Changes in
cardiovascular risk factors from baseline values during the walking tour for the faster walking speed group (eCe) and the slower
walking speed group (e-e). Measurements were conducted at day 0 and every other day. Data are presented as mean with SEM.
Table 2 The effect of walking speed in km/h on the changes per 2 days in cardiovascular risk factors
HDL cholesterol LDL cholesterol Total cholesterol Triglycerides Systolic BP
b (95% CI) b (95% CI) b (95% CI) b (95% CI) b (95% CI)
Model I 0.03 (0.02 to 0.05)* 0.02 ( 0.02 to 0.06) 0.05 (0.01 to 0.09)*  0.02 ( 0.06 to 0.03) 0.03 ( 0.74 to 0.80)
Model II 0.04 (0.02 to 0.05)* 0.02 ( 0.02 to 0.06) 0.05 (0.01 to 0.10)*  0.01 ( 0.06 to 0.03)  0.07 ( 0.84 to 0.70)
Model III 0.04 (0.02 to 0.05)* 0.03 ( 0.01 to 0.07) 0.06 (0.02 to 0.10)* 0.00 ( 0.05 to 0.04)  0.07 ( 0.85 to 0.70)
Diastolic BP Weight Waist circ. Glucose
b (95% CI) b (95% CI) b (95% CI) b (95% CI)
Model I 0.01 ( 0.43 to 0.45) 0.06 ( 0.06 to 0.18) 0.15 ( 0.25 to 0.56)  0.01 ( 0.05 to 0.03)
Model II  0.01 ( 0.45 to 0.42) 0.05 ( 0.07 to 0.18) 0.07 ( 0.33 to 0.47)  0.02 ( 0.06 to 0.02)
Model III  0.03 ( 0.47 to 0.41) 0.06 ( 0.06 to 0.19) 0.18 ( 0.21 to 0.57) 0.00 ( 0.04 to 0.04)
The regression coefﬁcient b (with 95% CI) denotes the mean change in the risk factor per 2 days which is associated with a 1 km/h higher
walking speed. For example, a 1 km/h higher walking speed is associated with an increase in HDL cholesterol of 0.04 (95% CI 0.02 to
0.05) mmol/l (model III) per 2 days, translating to 0.24 (95% CI 0.12 to 0.30) mmol/l during the whole 12-day walking tour. Model I ¼ crude,
model II ¼ age and gender and model III ¼ age, gender, current smoking, BMI and heart rate at baseline.
*p<0.05.
BMI, body mass index; BP, blood pressure; waist circ., waist circumference; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
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The relation between walking speed and changes in cardiovascular risk factorsDifferences in walking speed were not related to changes
in blood pressure, weight, waist circumference, triglyc-
erides or glucose.
Several well-designed randomised controlled trials,
controlling for exercise volume, report no effects of
exercise intensity on plasma lipoproteins or on other
cardiovascular risk factors.
7e10 These trials describe long-
term changes (after 3e8 months) in cardiovascular risk
factors and the total weekly amount of exercise is limited
(not more than 3 h or 1000e1200 calories/week).
7e10
The present study describes changes in cardiovascular
risk factors during exercise, and the daily amount of
exercise in the current study was almost twice the
amount of weekly exercise in the trials described above
(5.3960.36 h daily in the present study).
Possibly, the changes in lipoproteins related to the
walking speed described in the current study are present
for a limited time span shortly after very large bouts of
exercise and are therefore not seen in the studies
described above. Other randomised trials report larger
decreases in weight, waist circumference and diastolic
blood pressure,
13 or larger increases in HDL-c,
12 for
higher compared with lower intensity exercise, but these
studies did not control for differences in the total
amount of exercise, so the reported effects could be due
to the higher exercise volume instead of the higher
intensity. In the present study, all participants walked
almost the same distance and in addition, we adjusted
the analyses for the small differences in total walking
distance, which did not change the results.
There is no doubt that physical exercise should be
advised to everyone who is capable to exercise, as phys-
ical exercise has multiple beneﬁcial health effects.
1e3
Furthermore, more exercise is better, as there is a clear
inverse doseeresponse relationship between exercise
and all-cause mortality.
2 However, what walking speed is
optimal for improving the lipid proﬁle is not sure.
Should we advise people to walk with high speed or with
low speed when the goal is improvement of the lipid
proﬁle? In the present study, walking with higher speed
increases HDL-c more, but at the expense of less LDL-c
decrease, and walking with lower speed leads to less
HDL-c increase but a more profound LDL-c decrease.
Does the extra increase in HDL-c related to a higher
walking speed outweighs the less decrease in LDL-c? This
question cannot be answered with the results of the
current study. In general, the primary lipid target in the
prevention and treatment of cardiovascular disease is
LDL-c, which is best reached with lower walking speed,
according to the results of the present study. However, in
large prospective cohort studies in the healthy popula-
tion, an increased walking speed assessed by a question-
naire has been related to a lower risk for coronary heart
disease and diabetes, independent of walking
volume.
17e20 This ﬁnding can lead to the speculation
that the extra increase in HDL-c related to a higher
walking speed could be more important than the less
decrease in LDL-c. However, drawing conclusions from
the combined ﬁndings of these two completely different
types of studies is a step to far.
Several physiological mechanisms can be considered
to explain the exercise-induced and intensity-indepen-
dent changes in LDL-c and HDL-c. Exercise-induced
changes in LDL-c may be due to dilution as a result of an
increase in plasma volume,
23 a decrease in body weight
or a change in body fat distribution,
24 an upregulated
expression of hepatic LDL receptors,
25 an increased
cholesterol transfer from apoA-containing particles
(LDL-c, very-low-density lipoprotein) to HDL particles
26
and the use of cholesterol for cellular metabolism and
repair due to muscle damage immediately after intense
exercise.
23 Exercise-induced HDL-c changes may be
explained by the increased acceptance of free choles-
terol from peripheral tissues by nascent HDL particles,
27
increased HDL particle maturation by cholesterol ester-
iﬁcation due to increased lecithin:cholesterol acyl-
transferase,
28 increased breakdown of triglyceride-rich
particles resulting from an increased lipoprotein lipase
activity, leading to uptake of the cholesterol content by
HDL-c particles,
29 which could lead to prolonged HDL
Table 3 The effect of walking speed in 1000 steps/h on the changes per 2 days in cardiovascular risk factors
HDL cholesterol LDL cholesterol Total cholesterol Triglycerides Systolic BP
b (95% CI) b (95% CI) b (95% CI) b (95% CI) b (95% CI)
Model I 0.01 (0.00 to 0.02)* 0.02 (0.00 to 0.04)* 0.02 (0.00 to 0.05)*  0.01 ( 0.03 to 0.01)  0.41 ( 0.81 to  0.01)*
Model II 0.01 (0.00 to 0.02)* 0.02 (0.00 to 0.04)* 0.02 (0.00 to 0.05)*  0.01 ( 0.03 to 0.01)  0.40 ( 0.79 to  0.00)*
Model III 0.01 (0.00 to 0.02)* 0.02 (0.00 to 0.04)* 0.03 (0.00 to 0.05)* 0.00 ( 0.03 to 0.02)  0.36 ( 0.76 to 0.04)
Diastolic BP Weight Waist circ. Glucose
b (95% CI) b (95% CI) b (95% CI) b (95% CI)
Model I  0.10 ( 0.33 to 0.13) 0.01 ( 0.05 to 0.08) 0.09 ( 0.12 to 0.30) 0.00 ( 0.03 to 0.02)
Model II  0.09 ( 0.32 to 0.14) 0.01 ( 0.05 to 0.08) 0.09 ( 0.12 to 0.30)  0.01 ( 0.03 to 0.02)
Model III  0.06 ( 0.29 to 0.17) 0.01 ( 0.05 to 0.08) 0.12 ( 0.08 to 0.32) 0.00 ( 0.02 to 0.02)
The regression coefﬁcient b (with 95% CI) denotes the mean change in the risk factor per 2 days which is associated with a 1000 steps/h higher
walking speed. For example, a 1000 steps/h higher walking speed is associated with an increase in HDL cholesterol of 0.01 (95% CI 0.00 to
0.02) mmol/l (model III) per 2 days, translating to 0.06 (95% CI 0.00 to 0.12) mmol/l during the whole 12-day walking tour. Model I ¼ crude,
model II ¼ age and gender and model III ¼ age, gender, current smoking, BMI and heart rate at baseline.
*p<0.05.
BMI, body mass index; BP, blood pressure; waist circ., waist circumference; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
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30 and ﬁnally a decrease in cholesteryl
ester transfer protein leading to a reduced shift of
cholesterol esters from HDL to non-HDL lipoproteins.
31
Which of these mechanisms is responsible for the
observed increases in HDL-c and LDL-c related to higher
walking speed in the present study is unknown. We did
not measure (markers of) plasma volume changes,
which could possibly be of inﬂuence on the results.
However, as the reported results are linear during
12 days, and the measurements were conducted early in
the morning, more than 12 h after the ending of the
previous walking stage, we believe the inﬂuence of
changes in plasma volume on the results to be small.
Furthermore, we showed in an exploratory analysis that
the relationship between walking speed and changes in
blood lipids were not explained by changes in body
weight. As the differences between the slower and faster
walking speed groups occurred rapidly, within several
days, and the amount of daily exercise was large, it is
conceivable that consumption of cholesterol, from both
HDL and LDL particles, for cellular metabolism and
cellular repair due to muscle damage contributes to the
observed changes. This explanation is more likely than
other more long-term metabolic adaptations. The
overall duration of exercise could have a higher impact
than the small differences in intensity of this exercise on
the amount of cholesterol needed for cellular metabo-
lism and repair of muscle damage, leading to less
increase in HDL-c and more decrease in LDL-c with
longer exercise at a lower walking speed.
Walking a pilgrimage requires a considerable amount
of time, a thorough preparation and a good physical and
mental health. Our ﬁndings can be generalised to
healthy middle-aged men and women who satisfy these
conditions, and possibly to other types of exercise,
consisting of prolonged daily periods of moderate
intensity. However, the results of the present study are
based on a relatively small group of subjects walking
281 km in 12 days. Therefore, no statistical interaction
tests and no subgroup analyses could be performed.
Whether the relationship between walking speed and
the change in lipoproteins can be extrapolated to
smaller amounts or other types of exercise is not known.
The current study reports pragmatic research about
exercise in real-life; however, more research needs to be
done in a controlled lab-based setting in order to fully
explore and understand the results of this study. A
strength of this study is the equal amount of exercise, in
this case the total walking distance, for all participants,
eliminating this factor as a possible confounder in the
relationship between walking speed and changes in
cardiovascular risk factors. Furthermore, walking speed
was measured and not assessed with a questionnaire like
in many cohort studies, and the consistent results for
walking speed expressed in kilometres per hour and
steps per hour strengthen our ﬁndings.
We also acknowledge study limitations. Participants
walking with slower speed were metabolically
unhealthier as baseline than subjects walking with faster
speed. Whether the worse baseline metabolic proﬁle
(such as higher BMI) is the cause of the slower walking
speed achieved, or the consequence of, for example,
a lower physical ﬁtness which also results in a slower
walking speed, is unclear and cannot be determined
from the present study. Therefore, we adjusted the
mixed linear effect models for baseline differences
between the faster and slower walking speed groups,
which did not change the results. Furthermore, we were
not able to adjust for differences in the dietary pattern
or cardiorespiratory ﬁtness level of the participants, as
these variables were not measured. However, by
adjusting for the heart rate at baseline as a proxy for
cardiorespiratory ﬁtness and for other variables related
to cardiorespiratory ﬁtness or unhealthy dietary intake
such as age, gender, BMI and smoking, residual
confounding of cardiorespiratory ﬁtness or dietary
intake is unlikely.
In conclusion, during a 12-day walking tour to
Santiago de Compostela with long daily walking stages,
walking the same distance with a higher walking speed
was related to a more pronounced increase in HDL-c,
but to less decrease in LDL-c and total cholesterol,
independent of changes in body weight, in healthy
middle-aged men and women.
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